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Abstract
Background: In the last two decades, pregnancy rates for patients undergoing in-vitro fertilisation (IVF) have
significantly increased. Some of the major advances responsible for this improvement were the introduction of
controlled ovarian stimulation (COS) for the induction of multiple follicle development, and the utilisation of mid-
luteal gonadotropin-releasing hormone agonists to achieve pituitary down-regulation and full control of the cycle.
As a result, a combination of a gonadotropin-releasing hormone agonist with high doses (150-450 IU/day) of
recombinant follicle-stimulating hormone has become the current standard approach for ovarian stimulation.
However, given the heterogeneity of patients embarking on IVF, and the fact that many different drugs can be
used alone or in different combinations (generating multiple potential protocols of controlled ovarian stimulation),
we consider the need to identify special populations of patients and adapt treatment protocols accordingly, and to
implement a more individualised approach to COS.
Discussion: Studies on mild, minimal and natural IVF cycles have yielded promising results, but have focused on fresh
embryo transfers and included relatively young patient populations who generally have the potential for more
favourable outcomes. The efficacy of these protocols in patients with a poorer prognosis remains to be tested. When
comparing protocols for COS, it is important to think beyond current primary endpoints, and to consider the ideal quality
a n dq u a n t i t yo fo o c y t e sa n de m b r y o sb e i n gp r o d u c e dp e rstimulated patient, in order to achieve a pregnancy. We
should also focus on the cumulative pregnancy rate, which is based on outcomes from fresh and frozen embryos from
the same cycle of stimulation. Individualised COS (iCOS) determined by the use of biomarkers to test ovarian reserve has
the potential to optimise outcomes and reduce safety issues by adapting treatment protocols according to each patient’s
specific characteristics. As new objective endocrine, paracrine, functional and/or genetic biomarkers of response are
developed, iCOS can be refined further still, and this will be a significant step towards a personalised approach for IVF.
Conclusions: A variety of COS protocols have been adopted, with mixed success, but no single approach is
appropriate for all patients within a given population. We suggest that treatment protocols should be adapted for
individual patients through iCOS; this approach promises to be one of the first steps towards implementing
personalised medicine in reproductive science.
Background
Since the first successful IVF-embryo transfer (IVF-ET)
was carried out in 1978, the treatment of infertility has
advanced significantly [1]. The subsequent introduction
of COS for multiple follicular development significantly
increased pregnancy rates [2]. Such stimulation
protocols have now been developed and refined for
more than 25 years in an attempt to obtain an optimal
number of oocytes from each treatment cycle, and to
maximise pregnancy rates per fresh ET.
A significant milestone in the development of COS
was the implementation of gonadotropin-releasing hor-
mone (GnRH) agonists for pituitary suppression, from
the mid-luteal phase of the prior cycle until the comple-
tion of the COS process (long protocol). This approach
allows IVF centres to manage patients more easily,
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before the introduction of GnRH agonists) [3,4], results
in greater numbers of oocytes retrieved, and produces
better quality embryos and higher pregnancy rates than
older protocols [5]. In current care, the GnRH agonist
long protocol combined with high doses (150-450 IU/
day) of recombinant follicle-stimulating hormone (r-
FSH) continues to be the most commonly used COS
approach [6,7], although the use of human menopausal
gonadotropin (hMG) is also well established [8]. This
article will discuss proposed alternatives in clinical prac-
tice to the standard long protocol, the need to adapt
approaches for patients sub-populations, and finally will
consider the use of biomarkers as a tool for implement-
ing an individualised approach to COS treatment proto-
cols, and thus move into a new era of personalised
medicine.
Discussion
Alternative COS protocols and the need for individualised
treatment
The importance of achieving a good response to COS is
underscored by the fact that the number of oocytes
obtained following stimulation correlates positively with
the ongoing pregnancy rate (Figure 1) (data on file from
an unselected population of patients from the Instituto
Valenciano de Infertilidad, Valencia, Spain) [9]. How-
ever, a significant proportion of patients show a low or
poor response to the classical approach of the GnRH
agonist long protocol, which does not make it the ideal
choice for them. Consequently, several modifications
a n da l t e r n a t i v e sw i l lb ed i s c u s s e dt h a th a v eb e e ni n t r o -
duced to improve outcomes. These options should be
considered in the context that success rates for IVF
remain low, and that further individualising treatment
has the potential to produce significant improvement in
pregnancy rates.
Adjusting the standard protocols for COS
The ‘short’, ‘ultrashort’, ‘micro-flare’ and ‘stop’ GnRH
agonist protocols involve adjusting the timing and dose
of GnRH agonist administration, so that the patient bene-
fits from the initial flare-up of endogenous follicle stimu-
lating hormone (FSH) and luteinising hormone (LH) that
may ‘jump start’ the follicles, in addition to the action of
exogenous gonadotropins [10,11]. Another modification
to the standard long protocol involves changing the com-
bination of gonadotropins. For example, the addition of
LH has been shown to improve cycle outcomes in poor
responders and patients > 35 years old [12,13]. Moreover,
pre-treatment with testosterone [14,15], oestrogens [16]
or letrozole [17] has also been proposed to increase ovar-
ian response in this particular population.
Mild and minimal ovarian stimulation
The traditional approach of an agonist long protocol
which aims for an optimal number of oocytes, is not
without drawbacks. The protocol is time consuming and
involves complex regimens (at least 3 weeks of daily
injections) that cause considerable patient discomfort,
and has important short-term complications including
ovarian hyperstimulation syndrome (OHSS) and a high
incidence of multiple pregnancies. These negative
aspects lead to a high rate of drop-outs [18], and
increased costs [19]. As a result, alternative COS
approaches have been developed, whose aim is to opti-
mise the likelihood of achieving a healthy birth at a rea-
sonable cost, while ensuring patient comfort and
reducing the incidence of complications. These mild sti-
mulation protocols are less complex and time consum-
ing, less expensive, have lower drop-out rates, and are
hypothesised to have improved oocyte quality and endo-
metrial receptivity than the traditional approach [20].
Mild ovarian stimulation is based on two principles:
the use of GnRH antagonists, which cause immediate
and dose-dependent gonadotropin suppression [21], and
the concept that the impact of r-FSH on follicular
recruitment depends on the length of exposure above a
threshold, rather than the degree of FSH elevation [22].
This mild stimulation achieved similar pregnancy rates
per started cycle compared with the conventional regi-
men, or compared with the standard GnRH agonist long
protocol [23]. Furthermore, the use of this approach has
been shown to obtain a higher proportion of chromoso-
mally normal embryos than a conventional stimulation
strategy aimed at maximising oocyte yield [24] with less
psychological impact [25] and lower costs per year of
treatment [26].
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Figure 1 Relationship between number of oocytes retrieved
and ongoing pregnancy rate. Ongoing pregnancy rate according
to ovarian response in an unselected population (source: Instituto
Valenciano de Infertilidad, between 2004 and 2008, n = 7954, p <
0.000001 [Mantel-Hansen test for trend]).
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tion that has been proposed [27] uses clomiphene citrate
as an antagonist of hypothalamic oestradiol receptors,
thereby inhibiting both negative and positive feedback.
Thus, in the minimal ovarian stimulation protocol, clo-
miphene citrate is used both to stimulate follicular
development and to suppress ovulation. Pregnancy rates
per transfer (34.1%) and the number of viable vitrified
embryos (1.1 ± 1.5) were promising, and were signifi-
cantly higher with this regimen than an adjusted regi-
men using a lower dose of HMG or clomiphene citrate
alone, as shown in a retrospective analysis of 3654 cycles
[28].
Natural ovarian cycles
In any discussion of approaches to COS, natural and
modified natural cycles should be taken into account.
Natural cycles involve monitoring a patient’ss p o n t a -
neous cycle, and retrieving a single oocyte prior to the
LH peak; data show that this approach leads to a signifi-
cantly lower pregnancy rate than is achieved with stimu-
lated cycles [9]. In modified natural cycles, a cumulative
ongoing pregnancy rate of 30% after six cycles has been
reported, and the protocol has been proposed as a good
option before attempting COS IVF [29].
Comparing ovarian stimulation protocols
There have been very encouraging results from studies
on mild, minimal and natural ovarian stimulation
approaches, in which fresh ETs were used exclusively
[23,27-29]. However, the patients included in these stu-
dies were relatively young (mean age 33-34 years), lean
(body mass index [BMI] between 23 and 24), with nor-
mal ovarian reserve and mostly with male, tubal or
unexplained infertility, and so constitute a population in
which the outcomes of fertility treatment are generally
favourable. Unfortunately, the efficacy of these protocols
in patients with a poorer prognosis remains uncertain.
It is also important to consider the lack of reports on
the outcomes of pregnancies generated from frozen-
thawed IVF cycles. When only fresh ETs are analysed,
several published studies have been unable to detect a
significant difference between regimens [30-32]. It is
therefore inaccurate to consider only the results of sti-
mulation protocols that are based exclusively on fresh
transfers. Cumulative pregnancy rates are more mean-
ingful, being calculated by combining the outcomes
from fresh and frozen-thawed embryos from the same
cycle of stimulation. In our experience, a maximum of
8-9 retrieved mature oocytes is enough to achieve the
highest cumulative pregnancy rates. Any protocol of sti-
mulation that results in an increased number of good
quality oocytes per cycle will not lead to a higher chance
for a patient to become pregnant.
Furthermore, when considering what a successful out-
come means to a couple suffering from infertility, it is
important to remember that the most relevant measure
of success is the ability to have a single healthy child
delivered per initiated cycle, one patient, one embryo
and one baby [33]. To achieve this endpoint, it is of
paramount importance to individualise COS protocols
to be able to produce the optimal quantity and quality
of oocytes and embryos, and thereby to maximise the
chances of overall success. Without individualising treat-
ment, the current move towards single ET is likely to
have an adverse effect on pregnancy rates [34].
How can patients and protocols be matched?
Matching patients with the ideal COS protocol is diffi-
cult because the outcome of ovarian stimulation is
determined by many interacting factors (genetic and
non-genetic), which influence the level of response
achieved. The importance of each of these variables to
the final outcome should not be underestimated; for
example, the demographic characteristics of patients
undergoing IVF have a crucial impact on the chances of
success. Besides the well known impact of age [35] and
ovarian reserve [9], the presence of endometriosis [36],
polycystic ovaries [37] and a high BMI [38], can also
affect ovarian response and/or cycle outcome. In reality,
IVF units encounter a great variety of pathologies.
Table 1 shows the demographic characteristics of a
population undergoing IVFi nal a r g eu n i v e r s i t y -
affiliated unit; the proportion of patients with a good
prognosis was only 32%. Furthermore, in patients with
the same pathologies, genetic differences may predispose
some individuals to respond better to one stimulation
protocol over another. Fortunately, as described pre-
viously, there are many different options for COS, based
on different combinations of GnRH analogues and sti-
mulation drugs (Table 2). However, given the factors
mentioned above, it is inaccurate to put forward one
single protocol for a particular patient group, when
there may be considerable genetic variation within that
population. At the present time, COS is generally being
utilised in an empirical way; and unfortunately, trial-
and-error methodology is the most frequent path for
infertile patients. The type of protocol that is selected
for a patient is dependent on multiple factors, including
physician experience, the individual patient pathology,
age, BMI and practice guidelines of individual fertility
clinics.
Individualised COS (iCOS): the first step towards
personalised medicine
The diversity seen in the population of fertility patients,
means that continuing with a single approach to treat-
ment is unlikely to further improve outcomes.
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areas in that personalised medicine and customised
therapy is still under some development, and there are
several barriers to overcome [39]. On one side, some
pharmaceutical companies involved in the fertility field
promote a blockbuster model, focused on developing
and marketing drugs for use in as broad a patient group
as possible, while discouraging the development of
therapies for smaller sub-populations and the diagnostic
tests that can identify those sub-populations. On the
other side, regulatory agencies cause too many resources
to be devoted to Phase III clinical trials, which mean
that very few resources are available for post-approval
drug monitoring and assessment. In addition, clinicians’
daily practice is often empirical, despite the availability
of diagnostic tests that could guide more personalised
prescription of drugs and procedures. A further issue is
that clinical trials for new drugs generally use the best
population of patients to capture data against a com-
parator under ideal conditions. However, this population
often represents only a small proportion of the patients
typically seen in day-to-day clinical practice.
The adoption and expansion of iCOS through the
application of a combination of biomarkers of ovarian
reserve, follicle recruitment and genetic configuration of
the receptors for the hormones utilised is required.
Pharmacogenomics is the branch of pharmacology,
which examines the influence of genetic variability on
the variation in the response to drugs seen between
patients. By studying correlations between gene expres-
sion or single-nucleotide polymorphisms and the effi-
cacy or toxicity of a drug, pharmacogenomics aims to
provide a rational way to optimise drug therapy accord-
ing to the patient’s genotype, to ensure maximum effi-
cacy with minimal adverse effects. Such approaches
promise the advent of ‘personalised medicine’,i nw h i c h
drugs and drug combinations are tailored to each indivi-
dual’s unique genetic make-up. As an example of the
issues which this approach may help to address, the
study of Shahine and colleagues has recently shown that
Asian women had significantly lower implantation, clini-
cal pregnancy, and live birth rates than Caucasian
women, even though the population was composed
exclusively of women in whom only the highest quality
embryos had been transferred [40]. In addition, a study
on FSH receptor gene polymorphisms has suggested
that variation in the response to FSH is related to the
fact that women with ovarian dysfunction tend to carry
the Ser/Ser allelic variant, whereas good responders
more often carry the Asn/Ser allelic variant, which has a
higher FSH sensitivity [41]. Further work to clarify the
utility of FSH receptor gene polymorphisms is needed
[42].
The analysis of LH receptor polymorphisms has also
produced interesting results. It has been shown that the
incidence of a common LH receptor polymorphism is
significantly higher in patients needing high doses of r-
FSH for COS [43]. In addition, these patients have been
shown to have a better outcome when recombinant LH
is added to r-FSH for COS [44,45]. Therefore, this
approach could be useful for determining the need for
LH in a particular population undergoing COS.
iCOS: how to customise IVF treatment using biomarkers
As previously discussed, patient age, hormonal status,
PCOS, endometriosis and previous response to COS are
Table 1 Characteristics of patients undergoing IVF in the
Instituto Valenciano de Infertilidad between 2004 and
2008 (n = 7954)
Characteristics Age group (years)
≤35 36-40 > 40
BMI < 25 ≥ 25 < 25 ≥ 25 < 25 ≥ 25
Normo ovulatory (%) 31.9 5.6 19.3 4.1 7 1.8
Anovulation/PCOS (%) 4.5 2.5 1.4 0.9 0.06 0.04
Low responders (%) 4.4 0.7 3.6 0.6 0.34 0.06
Endometriosis (%) 5.7 0.4 2.7 0.2 0.18 0.02
Table 2 Choices for COS according to possible combinations of GnRH agonist/antagonist and stimulation drugs
GnRH agonist/antagonist protocol
GnRH agonist GnRH antagonist No GnRH analogue
Long Short Micro flare Standard Mild Modified
natural
Mini Natural
Gonadotropins and other agents
FSH
HMG
FSH + LH
Others: Clomiphene
Letrozole
Testosterone
Oestrogens
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the outcome of IVF. We already treat patients differently
depending on these characteristics, however, there are
further clinical features that indicate patients who may
benefit from COS tailored to their specific needs. It is
feasible to further define every patient before starting a
COS cycle, by analysing various endocrine/paracrine
biomarkers, including FSH, anti-Müllerian hormone
(AMH) or inhibin B hormone levels, as well as func-
tional biomarkers such as antral follicle count (AFC)
[46]. These biomarkers can provide a very specific char-
acterisation of a particular patient and each has its own
advantages (Table 3),
Day 3 FSH, oestradiol and inhibin B have traditionally
been used as indicators of ovarian reserve. Inhibin B is a
protein produced by the granulosa cells of pre-and
early-antral follicles, and circulating levels of inhibin B
are highest during the earliest and mid-stages of the
normal menstrual cycle [47]. FSH and oestradiol also
vary during the menstrual cycle and even though these
molecules were suggested as direct biomarkers of ovar-
ian reserve over a decade ago, there is still some doubt
as to the validity of this hypothesis, and further clarifica-
tion is needed [46,48-51].
AFC can be used as an indicator of the number of fol-
licles present. AFC does not change during the men-
strual cycle [52] but has been shown to steadily decrease
during the reproductive years. This decline in AFC is in
line with the belief that the number of antral follicles
indicates the size of the primordial follicle pool [53].
However, AFC is of limited clinical value for use in the
prediction of pregnancy [46].
AMH is a member of the transforming growth factor-
b family, and is the first predictive paracrine biomarker
used to anticipate the magnitude of ovarian response in
women undergoing IVF. AMH is primarily a product of
the granulosa cells in the pre-antral and small-antral fol-
licles [54] and correlates with AFC. AMH appears to be
more accurate in predicting ovarian response than
patient age, ovarian volume or day 3 levels of FSH, oes-
tradiol or inhibin B [55]. An additional benefit of AMH,
is that it is a stable biomarker within and between
menstrual cycles [56,57], removing the need for cycle
stage dependent blood samples or ultrasound scans.
Serum AMH currently has the strongest predictive cap-
ability for ovarian response and pregnancy for couples
with advanced female age or absence of male factors
[58].
A recent review of over 20 retrospective and prospec-
t i v es t u d i e so ft h eu s eo fA M Ha sam a r k e ro fo v a r i a n
response to COS showed a positive correlation between
basal AMH serum levels and the number of retrieved
oocytes in women undergoing ovarian stimulation [59].
There have been a limited number of studies published
to date on the relationship between AMH levels and
OHSS, however, studies show that hyper stimulation
and OHSS may be associated with higher mean basal
AMH levels [55,60-65]. The studies by Lee et al. and
Nardo et al. showed that basal AMH levels above 3.5
ng/ml are good predictors of hyper response and OHSS,
and patients who fall into this group may benefit from
the use of milder, more patient-friendly stimulation pro-
tocols [64,65].
Further evidence of the use of AMH and AFC as pre-
dictors of hyper response in COS was provided by Broer
et al. who conducted a systematic review and meta-ana-
lysis of the existing literature. The authors concluded
that AMH and AFC levels could potentially be used to
individualise FSH dosing regimens during COS [66]. It
is important to note that AMH levels can also be useful
in identifying oocyte donors who are at risk of develop-
ing OHSS, and assist in appropriate dose adjustment
[67].
There have been very few studies that have investi-
gated the relationship between serum AMH levels fol-
lowing IVF, and the number of live births achieved.
Nelson et al., 2007 demonstrated in a prospective study
of 340 women that the live birth rate increased with
increasing basal AMH levels. However, this was only
seen in women with basal AMH levels < 7.8 pmol/L
[55].
It is likely that AMH cannot predict if a patient will
become pregnant, but that it can predict patients who
have a higher probability of becoming pregnant follow-
ing IVF, as well as identifying those at higher risk of
developing OHSS.
In addition to only looking at AMH levels and out-
come of IVF, a recent prospective cohort study of 538
women by Nelson et al., 2009 went a step further and
investigated the relationship between AMH levels and
the success of different IVF treatment protocols.
Women with high AMH levels (> 15 pmol/L), classified
as high responders, who had a low starting dose of FSH
followed by a GnRH antagonist protocol rather than an
agonist protocol, eliminated the need for complete cryo-
preservation of embryos due to excess response. These
Table 3 Characteristics of potential markers for response
to COS (where +++ = degree to which a characteristic is
present)
Characteristics of an effective marker Age AMH FSH AFC
Prediction of poor response + +++ ++ +++
Prediction of hyper response + +++ - ++
Low inter-cycle variability +++ ++ - ++
Low intra-cycle variability +++ ++ - ++
Applicable to all patients +++ +++ + +
Low cost of applying test +++ - - -
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rate and fewer hospitalisations for OHSS. Women with
normal AMH levels (5-15 pmol/L) treated with a tradi-
tional GnRH agonist long protocol, showed a low inci-
dence of excess response and poor response. Finally,
women with low AMH (1- < 5 pmol/L), classified as
reduced responders, exhibited a suboptimal response to
COS and low pregnancy rates irrespective of the treat-
ment strategy used [68].
In addition to the hormone and functional biomarkers
mentioned, genetic traits and abnormalities can also
influence fertility and could provide further biomarkers.
Identification and in vitro characterisation of four
abnormal FSH receptor variants indicates that screening
of patients before embarking on stimulation with FSH
may be beneficial for success [69]. It has also been sug-
gested that hyposensitivity to FSH may be caused by an
abnormal variant of the FSH receptor that reduces sen-
sitivity to the receptor [70]. Mutations in the genes cod-
ing for LH [71-75] and the LH receptor [76-78] have
been identified and these mutations may play a role in
the cause of infertility, as well as influence the success
or failure of fertility treatment. Further, it has been sug-
gested that assessing serum androgen levels prior to
initiation of COS may be beneficial for the selection of
gonadotropin starting doses. An assessment of theca cell
function following a GnRH agonist stimulation test
prior to the initiation COS revealed that serum steroid
levels correlated with AFC, as well as with sensitivity to
FSH [79].
There is also currently a large body of work underway
to find novel and objective biomarkers for oocyte and
embryo quality, and for other factors such as endome-
trial status, [58,80,81], which in the future may offer the
possibility of refining IVF even further. Further large-
scale studies to determine the relationship between
levels of biomarker such as AMH and the success of dif-
ferent IVF treatment protocols in different patient popu-
lations are required to fully realise the future potential
of IVF success.
The future potential of increased IVF success through the
development and implementation of iCOS
Today, after 30 years of IVF practice, the live birth rate
for patients with a very good prognosis is still below
50%. Taking a qualitative leap in IVF techniques, by
introducing a more individualised approach such as
iCOS could dramatically improve results and reduce
safety issues. We must match the right drugs and proto-
cols of stimulation to the right patients. By developing
technologies to improve culture conditions and to objec-
tively identify the gametes that will generate embryos
with high implantation potential, the extent of the
improvements that iCOS can facilitate is almost
unimaginable. To complete the circle, if we develop
technologies that allow us to define endometrial recep-
tivity status, we will be able to revolutionise the system,
and therefore achieve the best outcomes for the benefit
of our patients.
We foresee a future in which patients will be tested to
define their endocrine/paracrine status and genetic
make-up to define a path for iCOS that will be adapted
according to their individual needs. The iCOS protocols
will be designed to produce an ideal number of high
quality oocytes and embryos, and advanced technologies
will allow us to select the optimal embryo to transfer.
Single ET, vitrification and objective uterine receptivity
tests will maximise each patient’s chance of achieving a
successful pregnancy.
Conclusions
The introduction of COS to IVF approaches has signifi-
cantly improved outcomes, but current stimulation pro-
tocols are not optimal for all patient groups. In addition,
COS regimens are complex and may have negative
effects such as OHSS. Alternatives to standard COS pro-
tocols, including mild and natural cycles, have shown
some success, but no single approach is appropriate for
all patients in a given population. We propose that
treatment should be adapted for individual patients
through iCOS and that, together with the further devel-
opment of objective biomarkers of response, will be an
important first step towards implementing personalised
medicine in reproductive science.
List of abbreviations
AFC: antral follicle count; AMH: anti-Müllerian hormone; BMI: body mass
index; COS: controlled ovarian stimulation; FSH: follicle-stimulating hormone;
GnRH: gonadotropin-releasing hormone; HMG: human menopausal
gonadotropin; iCOS: individualised controlled ovarian stimulation; IVF-ET: in-
vitro fertilisation-embryo transfer; LH: luteinising hormone; OHSS: ovarian
hyperstimulation syndrome; PCOS: polycystic ovary syndrome; r-FSH:
recombinant follicle-stimulating hormone.
Acknowledgements
The authors would like to thank Cheryl Wright for her medical writing
assistance. Cheryl Wright is a Principal Medical Writer with Gardiner-Caldwell
Communications, UK. Funding for medical writing support was provided by
Merck Serono S.A.-Geneva.
Author details
1Instituto Valenciano de Infertilidad, Valencia, Spain.
2Merck Serono S.A.,
Geneva, Switzerland.
Authors’ contributions
EB and DE agreed the scope of this article, prepared the initial draft, and
reviewed the manuscript at all stages. They are fully and equally responsible
for the content of the article. Both authors read and approved the final
manuscript.
Competing interests
EB has received consultation fees from Merck-Serono and Schering Plough,
and honoraria for participating in sponsored symposiums by Merck-Serono
S.A.-Geneva, Schering Plough and Ferring Pharmaceuticals. DE is an
Bosch and Ezcurra Reproductive Biology and Endocrinology 2011, 9:82
http://www.rbej.com/content/9/1/82
Page 6 of 9employee of Merck Serono S.A.-Geneva, Switzerland (an affiliate of Merck
KGaA, Darmstadt, Germany).
Received: 25 January 2011 Accepted: 21 June 2011
Published: 21 June 2011
References
1. Steptoe PC, Edwards RG: Birth after the reimplantation of a human
embryo. Lancet 1978, 12:366.
2. Trounson AO, Leeton JF, Wood C, Webb J, Wood J: Pregnancies in
humans by fertilization in vitro and embryo transfer in the controlled
ovulatory cycle. Science 1981, 212:681-682.
3. Loumaye E: The control of endogenous secretion of LH by
gonadotrophin-releasing hormone agonists during ovarian
hyperstimulation for in-vitro fertilization and embryo transfer. Hum
Reprod 1990, 5:357-376.
4. Balasch J: GnRH agonist protocols: which one to use? In Female Infertility
Therapy: Current Practice. Edited by: Shoham Z, Jacobs HS, Howles CM.
London, UK: Martin Dunitz Ltd; 1998:89-203.
5. Hughes EG, Fedorkow DM, Daya S, Sagle MA, Van de Koppel P, Collins JA:
The routine use of gonadotropin-releasing hormone agonists prior to in
vitro fertilization and gamete intrafallopian transfer: a meta-analysis of
randomized controlled trials. Fertil Steril 1992, 58:888-896.
6. FIVNAT: French National Register on in vitro fertilization. Contracept Fertil
Sex 1997, 25:499-502, 1996 report.
7. Macklon NS, Stouffer RL, Giudice LC, Fauser BC: The science behind 25
years of ovarian stimulation for in vitro fertilization. Endocr Rev 2006,
27:170-207.
8. Coomarasamy A, Afnan M, Cheema D, van der Veen F, Bossuyt PM, van
Wely M: Urinary hMG versus recombinant FSH for controlled ovarian
hyperstimulation following an agonist long down-regulation protocol in
IVF or ICSI treatment: a systematic review and meta-analysis. Hum
Reprod 2008, 23:310-315.
9. Verberg MF, Eijkemans MJ, Macklon NS, Heijnen EM, Baart EB, Hohmann FP,
Fauser BC, Broekmans FJ: The clinical significance of the retrieval of a low
number of oocytes following mild ovarian stimulation for IVF: a meta-
analysis. Hum Reprod Update 2009, 15:5-12.
10. Detti L, Williams DB, Robins JC, Maxwell RA, Thomas MA: A comparison of
three downregulation approaches for poor responders undergoing in
vitro fertilization. Fertil Steril 2005, 84:1401-1405.
11. Loutradis D, Vomvolaki E, Drakakis P: Poor responder protocols for in-vitro
fertilization: options and results. Curr Opin Obstet Gynecol 2008,
20:374-378.
12. Mochtar MH, Van der Veen, Ziech M, van Wely M: Recombinant
Luteinizing Hormone (rLH) for controlled ovarian hyperstimulation in
assisted reproductive cycles. Cochrane Database Syst Rev 2007, 18:2.
13. Bosch E, Labarta E, Crespo J, Simón C, Remohí J, Pellicer A: Impact of
luteinizing hormone administration on gonadotropin-releasing hormone
antagonist cycles: an age-adjusted analysis. Fertil Steril 2010.
14. Fábregues F, Peñarrubia J, Creus M, Manau D, Casals G, Carmona F,
Balasch J: Transdermal testosterone may improve ovarian response to
gonadotrophins in low-responder IVF patients: a randomized, clinical
trial. Hum Reprod 2009, 24:349-359.
15. Kim CH, Howles CM, Lee HA: The effect of transdermal testosterone gel
pretreatment on controlled ovarian stimulation and IVF outcome in low
responders. Fertil Steril 2010.
16. Fanchin R, Méndez Lozano DH, Schonäuer LM, Cunha-Filho JS, Frydman R:
Hormonal manipulations in the luteal phase to coordinate subsequent
antral follicle growth during ovarian stimulation. Reprod Biomed Online
2005, 10:721-728.
17. Garcia-Velasco JA, Moreno L, Pacheco A, Guillén A, Duque L, Requena A,
Pellicer A: The aromatase inhibitor letrozole increases the concentration
of intraovarian androgens and improves in vitro fertilization outcome in
low responder patients: a pilot study. Fertil Steril 2005, 84:82-87.
18. Verberg MF, Eijkemans MJ, Heijnen EM, Broekmans FJ, de Klerk C, Fauser BC,
Macklon NS: Why do couples drop-out from IVF treatment? A
prospective cohort study. Hum Reprod 2008, 23:2050-2055.
19. Goverde AJ, McDonnell J, Vermeiden JP, Schats R, Rutten FF, Schoemaker J:
Intrauterine insemination or in-vitro fertilisation in idiopathic subfertility
and male subfertility: a randomised trial and cost-effectiveness analysis.
Lancet 2000, 355:13-18.
20. Verberg MF, Macklon NS, Nargund G, Frydman R, Devroey P, Broekmans FJ,
Fauser BC: Mild ovarian stimulation for IVF. Hum Reprod Update 2009,
15:13-29.
21. Frydman R, Cornel C, de Ziegler D, Taieb J, Spitz IM, Bouchard P:
Prevention of premature luteinizing hormone and progesterone rise
with a gonadotropin-releasing hormone antagonist, Nal-Glu, in
controlled ovarian hyperstimulation. Fertil Steril 1991, 56:923-927.
22. Schipper I, Hop WC, Fauser BC: The follicle-stimulating hormone (FSH)
threshold/window concept examined by different interventions with
exogenous FSH during the follicular phase of the normal menstrual
cycle: duration, rather than magnitude, of FSH increase affects follicle
development. J Clin Endocrinol Metab 1998, 83:1292-1298.
23. Hohmann FP, Macklon NS, Fauser BC: A randomized comparison of two
ovarian stimulation protocols with gonadotropin-releasing hormone
(GnRH) antagonist cotreatment for in vitro fertilization commencing
recombinant follicle-stimulating hormone on cycle day 2 or 5 with the
standard long GnRH agonist protocol. J Clin Endocrinol Metab 2003,
88:166-173.
24. Baart EB, Martini E, Eijkemans MJ, Van Opstal D, Beckers NG, Verhoeff A,
Macklon NS, Fauser BC: Milder ovarian stimulation for in-vitro fertilization
reduces aneuploidy in the human preimplantation embryo: a
randomized controlled trial. Hum Reprod 2007, 22:980-988.
25. de Klerk C, Macklon NS, Heijnen EM, Eijkemans MJ, Fauser BC, Passchier J,
Hunfeld JA: The psychological impact of IVF failure after two or more
cycles of IVF with a mild versus standard treatment strategy. Hum
Reprod 2007, 22:2554-2558.
26. Polinder S, Heijnen EM, Macklon NS, Habbema JD, Fauser BJ, Eijkemans MJ:
Cost-effectiveness of a mild compared with a standard strategy for IVF:
a randomized comparison using cumulative term live birth as the
primary endpoint. Hum Reprod 2008, 23:316-323.
27. Teramoto S, Kato O: Minimal ovarian stimulation with clomiphene citrate:
a large-scale retrospective study. Reprod Biomed Online 2007, 15:134-148.
28. Segawa T, Kato K, Kawachiya S, Takehara Y, Kato O: Evaluation of minimal
stimulation IVF with clomiphene citrate and hMG. Fertil Steril 2007, 88:
(Suppl 1):S286.
29. Pelinck MJ, Knol HM, Vogel NE, Arts EG, Simons AH, Heineman MJ, Hoek A:
Cumulative pregnancy rates after sequential treatment with modified
natural cycle IVF followed by IVF with controlled ovarian stimulation.
Hum Reprod 2008, 23:1808-1814.
30. Frydman R, Howles CM, Truong F: A double-blind randomized study to
compare recombinant human follicle stimulating hormone (FSH; Gonal-
F) with highly purified urinary FSH (Metrodin HP) in women undergoing
assisted reproductive techniques including intracytoplasmic sperm
injection. The French Multicentre Trialists. Hum Reprod 2000, 15:520-525.
31. Bergh C, Howles CM, Borg K, Hamberger L, Josefsson B, Nilsson L,
Wikland M: Recombinant human Follicle Stimulating Hormone (GONAL-f)
versus highly purified urinary FSH (Metrodin HP); results of a
randomized comparative study in women undergoing Assisted
Reproductive Techniques. Hum Reprod 1997, 12:2133-2139.
32. Al-Inany H, Aboulghar M, Mansour R, Serour G: Meta-analysis of
recombinant versus urinary-derived FSH: an update. Human Reproduction
2003, 18:305-313.
33. Min JK, Breheny SA, MacLachlan V, Healy DL: What is the most relevant
standard of success in assisted reproduction? The singleton, term
gestation, live birth rate per cycle initiated: the BESST endpoint for
assisted reproduction. Hum Reprod 2004, 19:3-7.
34. Roberts SA, Fitzgerald CT, Brison DR: Modelling the effect of single
embryo transfer in a national health service IVF programme. Hum Reprod
2009, 24:122-131.
35. Hourvitz A, Machtinger R, Maman E, Baum M, Dor J, Levron J: Assisted
reproduction in women over 40 years of age: how old is too old? Reprod
Biomed Online 2009, 19:599-603.
36. Barnhart K, Dunsmoor-Su R, Coutifaris C: Effect of endometriosis on in
vitro fertilization. Fertil Steril 2002, 77:1148-1155.
37. Heijnen EM, Eijkemans MJ, Hughes EG, Laven JS, Macklon NS, Fauser BC: A
meta-analysis of outcomes of conventional IVF in women with
polycystic ovary syndrome. Hum Reprod Update 2006, 12:13-21.
38. Bellver J, Ayllón Y, Ferrando M, Melo M, Goyri E, Pellicer A, Remohí J,
Meseguer M: Female obesity impairs in vitro fertilization outcome
without affecting embryo quality. Fertil Steril 2010, 93:447-454.
Bosch and Ezcurra Reproductive Biology and Endocrinology 2011, 9:82
http://www.rbej.com/content/9/1/82
Page 7 of 939. Aspinall MG, Hamermesh RG: Realizing the promise of personalized
medicine. Harv Bus Rev 2007, 85:108-117.
40. Shahine LK, Lamb LD, Lathi RB, Milki AA, Langen E, Westphal LM: Poor
prognosis with in vitro fertilisation in Indian women compared to
Caucasian women despite similar embryo quality. PLoS ONE 2009, 4:
e7599.
41. Loutradis D, Patsoula E, Minas V, Koussidis GA, Antsaklis A, Michalas S,
Makrigiannakis A: FSH receptor gene polymorphisms have a role for
different ovarian response to stimulation in patients entering IVF/ICSI-ET
programs. J Assist Reprod Genet 2006, 23:177-184.
42. Mohiyiddeen L, Nardo LG: Single-nucleotide polymorphisms in the FSH
receptor gene and ovarian performance: future role in IVF. Hum Fertil
(Camb) 2010, 13:72-78.
43. Alviggi C, Clarizia R, Pettersson K, Mollo A, Humaidan P, Strina I, Coppola M,
Ranieri A, D’Uva M, De Placido G: Suboptimal response to GnRHa long
protocol is associated with a common LH polymorphism. Reprod Biomed
Online 2009, 18:9-14.
44. Lisi F, Rinaldi L, Fishel S, Lisi R, Pepe G, Picconeri MG, Campbell A, Rowe P:
Use of recombinant FSH and recombinant LH in multiple follicular
stimulation for IVF: a preliminary study. Reprod Biomed Online 2001,
3:190-194.
45. Ruvolo G, Bosco L, Pane A, Morici G, Cittadini E, Roccheri MC: Lower
apoptosis rate in human cumulus cells after administration of
recombinant luteinizing hormone to women undergoing ovarian
stimulation for in vitro fertilization procedures. Fertil Steril 2007,
87:542-546.
46. Broekmans FJ, Kwee J, Hendriks DJ, Mol BW, Lambalk CB: A systematic
review of tests predicting ovarian reserve and IVF outcome. Hum Reprod
2006, 12:685-718.
47. Groome NP, Illingworth PJ, O’Brien M, Pai R, Rodger FE, Mather JP,
McNeilly AS: Measurement of dimeric inhibin B throughout the human
menstrual cycle. J Clin Endocrinol Metab 1996, 81:1401-1405.
48. Ravhon A, Lavery S, Michael S, Donaldson M, Margara R, Trew G, et al:
Dynamic assays of inhibin B and oestradiol following buserelin acetate
administration as predictors of ovarian response in IVF. Hum Reprod
2000, 15:2297-2301.
49. Bancsi LF, Broekmans FJ, de Jong FH, Habbema JD, te Velde ER: Predictors
of poor ovarian response in in vitro fertilization: a prospective study
comparing basal markers of ovarian reserve. Fertil Steril 2002, 77:328-336.
50. Seifer DB, Scott RT Jr, Bergh PA, Abrogast LK, Friedman CI, Mack CK,
Danforth DR: Women with declining ovarian reserve may demonstrate a
decrease in day 3 serum inhibin B before a rise in day 3 follicle-
stimulating hormone. Fertil Steril 1999, 72:63-65.
51. Hughes EG, Robertson DM, Handelsman DJ, Hayward S, Healy DL, de
Kretser DM: Inhibin and estradiol responses to ovarian hyperstimulation:
effects of age and predictive value for in vitro fertilization outcome. J
Clin Endocrinol Metab 1990, 70:358-364.
52. Hehenkamp WJ, Looman CW, Themmen AP, de Jong FH, Te Velde ER,
Broekmans FJ: Anti-Müllerian hormone levels in the spontaneous
menstrual cycle do not show substantial fluctuation. J Clin Endocrinol
Metab 2006, 91:4057-4063.
53. Scheffer GJ, Broekmans FJ, Dorland M, Habbema JD, Looman CW, te
Velde ER: Antral follicle counts by transvaginal ultrasonography are
related to age in women with proven natural fertility. Fertil Steril 1999,
72:845-851.
54. Weenen C, Laven JS, Von Bergh AR, Cranfield M, Groome NP, Visser JA,
Kramer P, Fauser BC, Themmen AP: Anti-Müllerian hormone expression
pattern in the human ovary: potential implications for initial and cyclic
follicle recruitment. Mol Hum Reprod 2004, 10:77-83.
55. Nelson SM, Yates RW, Fleming R: Serum anti-Müllerian hormone and FSH:
prediction of live birth and extremes of response in stimulated cycles-
implications for individualization of therapy. Hum Reprod 2007,
22:2414-2421.
56. Tsepelidis S, Devreker F, Demeestere I, Flahaut A, Gervy Ch, Englert Y:
Stable serum levels of anti-Müllerian hormone during the menstrual
cycle: a prospective study in normo-ovulatory women. Hum Reprod 2007,
22:1837-1840.
57. van Disseldorp J, Lambalk CB, Kwee J, et al: Comparison of inter-and intra-
cycle variability of anti-Mullerian hormone and antral follicle counts.
Hum Reprod 2010, 25:221-227.
58. Lee T, Liu HC, Huang CC, Hsieh KC, Lin PL, Lee MS: Impact of female age
and male infertility on ovarian reserve markers to predict outcome of
assisted reproduction technology cycles. Reprod Biol Endocrinol Online
2009, 7:100.
59. La Marca A, Sighinolfi G, Radi D, Argento C, Baraldi E, Artenisio AC,
Stabile G, Volpe A: Anti-Mullerian hormone (AMH) as a predictive marker
in assisted reproductive technology (ART). Hum Reprod Update 2010,
16:113-130.
60. Eldar-Geva T, Ben-Chetrit A, Spitz IM, Rabinowitz R, Markowitz E, Mimoni T,
Gal M, Zylber-Haran E, Margalioth EJ: Dynamic assays of inhibin B, anti-
Mullerian hormone and estradiol following FSH stimulation and ovarian
ultrasonography as predictors of IVF outcome. Hum Reprod 2005,
20:3178-3183.
61. Tremellen KP, Kolo M, Gilmore A, Lekamge DN: Anti-mullerian hormone as
a marker of ovarian reserve. Aust N Z J Obstet Gynaecol 2005, 45:20-24.
62. Nakhuda GS, Chu MC, Wang JG, Sauer MV, Lobo RA: Elevated serum
mullerian-inhibiting substance may be a marker for ovarian
hyperstimulation syndrome in normal women undergoing in vitro
fertilization. Fertil Steril 2006, 85:1541-1543.
63. La Marca A, Giulini S, Tirelli A, Bertucci E, Marsella T, Xella S, Volpe A: Anti-
Mullerian hormone measurement on any day of the menstrual cycle
strongly predicts ovarian response in assisted reproductive technology.
Hum Reprod 2007, 22:766-771.
64. Lee TH, Liu CH, Huang CC, Wu YL, Shih YT, Ho HN, Yang YS, Lee MS: Serum
anti-Mullerian hormone and estradiol levels as predictors of ovarian
hyperstimulation syndrome in assisted reproduction technology cycles.
Hum Reprod 2008, 23:160-167.
65. Nardo LG, Gelbaya TA, Wilkinson H, Roberts SA, Yates A, Pemberton P,
Laing I: Circulating basal anti-Mullerian hormone levels as predictor of
ovarian response in women undergoing ovarian stimulation for in vitro
fertilization. Fertil Steril 2008.
66. Broer SL, Dólleman M, Opmeer BC, Fauser BC, Mol BW, Broekmans FJ: AMH
and AFC as predictors of excessive response in controlled ovarian
hyperstimulation: a meta-analysis. Hum Reprod Update 2011, 17:46-54.
67. Nakhuda GS, Douglas NC, Thornton MH, Guarnaccia MM, Lobo R, Sauer MV:
Anti-Müllerian hormone testing is useful for individualization of
stimulation protocols in oocyte donors. Reprod Biomed Online 2010,
20:42-47.
68. Nelson SM, Yates RW, Lyall H, et al: Anti-Müllerian hormone-based
approach to controlled ovarian stimulation for assisted conception. Hum
Reprod 2009, 24:867-875.
69. Gerasimova T, Thanasoula MN, Zattas D, Seli E, Sakkas D, Lalioti MD:
Identification and in vitro characterization of follicle stimulating
hormone (FSH) receptor variants associated with abnormal ovarian
response to FSH. J Clin Endocrinol Metab 2010, 95:529-536.
70. Greb RR, Grieshaber K, Gromoll J, Sonntag B, Nieschlag E, Kiesel L,
Simoni M: A common single nucleotide polymorphism in exon 10 of the
human follicle stimulating hormone receptor is a major determinant of
length and hormonal dynamics of the menstrual cycle. J Clin Endocrinol
Metab 2005, 90:4866-4872.
71. Liao WX, Goh HH, Roy AC: Functional characterization of a natural variant
of luteinizing hormone. Hum Genet 2002, 111:219-224.
72. Huhtaniemi I, Pettersson K: Mutations and polymorphisms in the
gonadotrophin genes; clinical relevance. Clin Endocrinol 1998, 48:675-682.
73. Jiang M, Pakarinen P, Zhang FP, El-Hefnawy T, Koskimies P, Pettersson K,
Huhtaniemi I: A common polymorphic allele of the human luteinizing
hormone beta-subunit gene: additional mutations and differential
function of the promoter sequence. Hum Mol Genet 1999, 8:2037-2046.
74. Nilsson CH, Kaleva M, Virtanen H, Haavisto AM, Pettersson K, Huhtaniemi IT:
Disparate response of wild-type and variant forms of LH to GnRH
stimulation in individuals heterozygous for the LHbeta variant allele.
Hum Reprod 2001, 16:230-235.
75. Alviggi C, Clarizia R, Pettersen K, Mollo A, Humaidan P, Strina I, Coppola M,
Ranieri A, D’Uva M, De Placido G: Suboptimal response to GnRHa long
protocol is associated with a common LH polymorphism. Reprod Biomed
Online 2009, 18:9-14.
76. Gromoll J, Lahrmann L, Godmann M, Muller T, Michel C, Stamm S,
Simoni M: Genomic checkpoints for exon 10 usage in the luteinizing
hormone receptor type 1 and type 2. Mol Endocrinol 2007, 21:1984-1996.
77. Nordhoff V, Gromoll J, Simoni M: Constitutively active mutations of G
protein-coupled receptors: the case of the human luteinizing hormone
Bosch and Ezcurra Reproductive Biology and Endocrinology 2011, 9:82
http://www.rbej.com/content/9/1/82
Page 8 of 9and follicle-stimulating hormone receptors. Arch Med Res 1999,
30:501-509.
78. Akerman FM, Lei Z, Rao CV, Nakajima ST: A case of spontaneous ovarian
hyperstimulation syndrome with a potential mutation in the hCG/LH
receptor gene. Fertil Steril 2000, 74:403-404.
79. Hugues JN, Theron-Gerard L, Coussieu C, Pasquier M, Dewailly D, Cedrin-
Durnerin : Assessment of theca cell function prior to controlled ovarian
stimulation: the predictive value of serum basal/stimulated steroid
levels. Hum Reprod 2010, 25:228-234.
80. Revelli A, Delle Piane L, Casano S, Molinari E, Massobrio M, Rinaudo P:
Folicular fluid content and oocyte quality: from single biochemical
markers to metabolomics. Reprod Biol Endocrinol 2009, 7:40.
81. Haouzi D, Mahmoud K, Fourar M, Bendhaou K, Dechaud H, De Vos J,
Rème T, Dewailly D, Hamamah S: Identification of new biomarkers of
human endometrial receptivity in the natural cycle. Hum Reprod 2009,
24:198-205.
doi:10.1186/1477-7827-9-82
Cite this article as: Bosch and Ezcurra: Individualised controlled ovarian
stimulation (iCOS): maximising success rates for assisted reproductive
technology patients. Reproductive Biology and Endocrinology 2011 9:82.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Bosch and Ezcurra Reproductive Biology and Endocrinology 2011, 9:82
http://www.rbej.com/content/9/1/82
Page 9 of 9